Novel drugs and early polypharmacotherapy in status epilepticus

[1]  E. Giller,et al.  Ganaxolone , 2011, Neurotherapeutics.

[2]  A. Nekoui,et al.  Nonanesthetic Effects of Ketamine: A Review Article. , 2018, The American journal of medicine.

[3]  K. Kapur,et al.  Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus , 2018, JAMA neurology.

[4]  H. Goodkin,et al.  Status epilepticus: Role for etiology in determining response to benzodiazepines , 2018, Annals of neurology.

[5]  Manisha N. Patel,et al.  Neuroprotective Effects of AEOL10150 in a Rat Organophosphate Model , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  G. Schulert,et al.  Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade , 2018, Journal of Neuroinflammation.

[7]  E. Aronica,et al.  Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies , 2018, Neuropathology and applied neurobiology.

[8]  C. Robinson,et al.  A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus—A case report and review of the literature , 2017, SAGE open medical case reports.

[9]  Manisha N. Patel,et al.  Scavenging reactive oxygen species inhibits status epilepticus-induced neuroinflammation , 2017, Experimental Neurology.

[10]  Paolo Bazzigaluppi,et al.  Hungry Neurons: Metabolic Insights on Seizure Dynamics , 2017, International journal of molecular sciences.

[11]  A. Vezzani,et al.  High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy , 2017, Brain, Behavior, and Immunity.

[12]  J. Claassen,et al.  Brexanolone as adjunctive therapy in super‐refractory status epilepticus , 2017, Annals of neurology.

[13]  Dong Zhou,et al.  Inhibition of P2X7 Receptor Ameliorates Nuclear Factor-Kappa B Mediated Neuroinflammation Induced by Status Epilepticus in Rat Hippocampus , 2017, Journal of Molecular Neuroscience.

[14]  L. Bennet,et al.  Ganaxolone: A New Treatment for Neonatal Seizures , 2017, Front. Cell. Neurosci..

[15]  C. Wasterlain,et al.  Simultaneous triple therapy for the treatment of status epilepticus , 2017, Neurobiology of Disease.

[16]  M. Pillat,et al.  EP2 receptor agonist ONO-AE1-259-01 attenuates pentylenetetrazole- and pilocarpine-induced seizures but causes hippocampal neurotoxicity , 2017, Epilepsy & Behavior.

[17]  M. Avoli,et al.  Allopregnanolone decreases interictal spiking and fast ripples in an animal model of mesial temporal lobe epilepsy , 2017, Neuropharmacology.

[18]  Shengnan Wang,et al.  Glibenclamide ameliorates cerebral edema and improves outcomes in a rat model of status epilepticus , 2017, Neuropharmacology.

[19]  C. Stafstrom,et al.  Glycolytic inhibition by 2-deoxy-d-glucose abolishes both neuronal and network bursts in an in vitro seizure model. , 2017, Journal of neurophysiology.

[20]  C. Wasterlain,et al.  Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus , 2017, Epilepsia.

[21]  D. Ekstein,et al.  Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy , 2017, The AAPS Journal.

[22]  F. Rosenow,et al.  Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals , 2017, Epilepsy & Behavior.

[23]  M. Rogawski,et al.  First‐in‐man allopregnanolone use in super‐refractory status epilepticus , 2017, Annals of clinical and translational neurology.

[24]  M. Sperling,et al.  Randomized, double‐blind, placebo‐controlled phase 2 study of ganaxolone as add‐on therapy in adults with uncontrolled partial‐onset seizures , 2017, Epilepsia.

[25]  Jun Yin,et al.  Bumetanide reduce the seizure susceptibility induced by pentylenetetrazol via inhibition of aberrant hippocampal neurogenesis in neonatal rats after hypoxia-ischemia , 2017, Brain Research Bulletin.

[26]  R. Eavey,et al.  Treatment of experimental status epilepticus with synergistic drug combinations , 2017, Epilepsia.

[27]  D. Offen,et al.  Toll‐like receptor 3 deficiency decreases epileptogenesis in a pilocarpine model of SE‐induced epilepsy in mice , 2017, Epilepsia.

[28]  Anup D. Patel,et al.  Increasing Ketamine Use for Refractory Status Epilepticus in US Pediatric Hospitals , 2017, Journal of child neurology.

[29]  S. Hantus,et al.  New-Onset Refractory Status Epilepticus Associated With the Use of Synthetic Cannabinoids. , 2017, Psychosomatics.

[30]  A. Robichaud,et al.  The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication , 2017, Epilepsy & Behavior.

[31]  K. Borges,et al.  The effects of C5aR1 on leukocyte infiltration following pilocarpine‐induced status epilepticus , 2017, Epilepsia.

[32]  F. Dorandeu.  Ketamine for the treatment of (super) refractory status epilepticus? Not quite yet , 2017, Expert review of neurotherapeutics.

[33]  Tobias Engel,et al.  The ATP-Gated P2X7 Receptor As a Target for the Treatment of Drug-Resistant Epilepsy , 2017, Front. Neurosci..

[34]  G. Biagini,et al.  Decreased allopregnanolone levels in cerebrospinal fluid obtained during status epilepticus , 2017, Epilepsia.

[35]  D. Reddy.  Sex differences in the anticonvulsant activity of neurosteroids: Sex Differences in Anticonvulsant Neurosteroids , 2017 .

[36]  Francesco Brigo,et al.  Topiramate in the Treatment of Generalized Convulsive Status Epilepticus in Adults: A Systematic Review with Individual Patient Data Analysis , 2016, Drugs.

[37]  F. Benfenati,et al.  2‐Deoxy‐d‐glucose enhances tonic inhibition through the neurosteroid‐mediated activation of extrasynaptic GABAA receptors , 2016, Epilepsia.

[38]  E. Wirrell,et al.  Febrile infection‐related epilepsy syndrome treated with anakinra , 2016, Annals of neurology.

[39]  R. Dingledine,et al.  Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats , 2016, Neuropharmacology.

[40]  K. Kapur,et al.  Refractory Status Epilepticus in Children: Intention to Treat With Continuous Infusions of Midazolam and Pentobarbital* , 2016, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[41]  H. Jyonouchi,et al.  Intractable Epilepsy (IE) and Responses to Anakinra, a Human Recombinant IL-1 Receptor Agonist (IL-1ra): Case Reports , 2016 .

[42]  C. Wasterlain,et al.  Midazolam–ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits , 2016, Epilepsia.

[43]  R. Eavey,et al.  Benzodiazepine‐refractory status epilepticus: pathophysiology and principles of treatment , 2016, Annals of the New York Academy of Sciences.

[44]  E. Trinka,et al.  (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study , 2016, CNS Drugs.

[45]  Yi Wang,et al.  Interleukin-1 receptor is a target for adjunctive control of diazepam-refractory status epilepticus in mice , 2016, Neuroscience.

[46]  D. Reddy,et al.  Clinical Potential of Neurosteroids for CNS Disorders. , 2016, Trends in pharmacological sciences.

[47]  Jianxiong Jiang,et al.  Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. , 2016, Trends in pharmacological sciences.

[48]  Kathleen S. McGreevy,et al.  Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01) , 2016, BMJ Open.

[49]  F. Rosenow,et al.  Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus , 2016, Expert review of clinical pharmacology.

[50]  H. Huttner,et al.  Assessing the value of topiramate in refractory status epilepticus , 2016, Seizure.

[51]  C. Woolley,et al.  Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model , 2016, eLife.

[52]  S. Shorvon,et al.  Recent advances in status epilepticus. , 2016, Current opinion in neurology.

[53]  K. Olkkola,et al.  Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy , 2016, Clinical Pharmacokinetics.

[54]  L. Hirsch,et al.  Cannabidiol for epilepsy: trying to see through the haze , 2016, The Lancet Neurology.

[55]  I. Rosemergy,et al.  Cannabidiol oil in the treatment of super refractory status epilepticus. A case report , 2016, Seizure.

[56]  Sudhir Sivakumaran,et al.  Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus , 2016, Epilepsia.

[57]  A. Rossetti,et al.  Monotherapy or Polytherapy for First-Line Treatment of SE? , 2016, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[58]  Richard E Carson,et al.  Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action , 2016, Epilepsia.

[59]  M. Baulac,et al.  Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial , 2016, The Lancet Neurology.

[60]  J. Killestein.  Cannabinoids in the Treatment of Epilepsy. , 2016, The New England journal of medicine.

[61]  K. Chopra,et al.  On the anticonvulsant effect of allopregnanolone (a neurosteroid) in neonatal rats. , 2015, Life sciences.

[62]  V. Sabharwal,et al.  Propofol–ketamine combination therapy for effective control of super-refractory status epilepticus , 2015, Epilepsy & Behavior.

[63]  F. Rosenow,et al.  Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus , 2015, Expert review of clinical pharmacology.

[64]  F. Scorza,et al.  Enhanced nonsynaptic epileptiform activity in the dentate gyrus after kainate-induced status epilepticus , 2015, Neuroscience.

[65]  Orrin Devinsky,et al.  Cannabinoids in the Treatment of Epilepsy. , 2015, The New England journal of medicine.

[66]  F. Zeiler,et al.  Lidocaine for Status Epilepticus in Pediatrics , 2015, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[67]  Yao Fang,et al.  Ketamine for the treatment of refractory status epilepticus , 2015, Seizure.

[68]  D. Henshall,et al.  P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus , 2015, Epilepsy & Behavior.

[69]  E. Trinka,et al.  Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit , 2015, Epilepsy & Behavior.

[70]  L. Mirabile,et al.  Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation , 2015, Epilepsy & Behavior.

[71]  M. Bialer,et al.  The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus , 2015, Epilepsy & Behavior.

[72]  W. Löscher.  Single versus combinatorial therapies in status epilepticus: Novel data from preclinical models , 2015, Epilepsy & Behavior.

[73]  M. Avoli,et al.  Neurosteroidal modulation of in vitro epileptiform activity is enhanced in pilocarpine-treated epileptic rats , 2015, Neurobiology of Disease.

[74]  N. Marlow,et al.  Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial , 2015, The Lancet Neurology.

[75]  J. Teitelbaum,et al.  Lidocaine for status epilepticus in adults , 2015, Seizure.

[76]  A. Herzog.  Catamenial epilepsy: Update on prevalence, pathophysiology and treatment from the findings of the NIH Progesterone Treatment Trial , 2015, Seizure.

[77]  G. Shrestha,et al.  Intravenous ketamine for treatment of super-refractory convulsive status epilepticus with septic shock: A report of two cases , 2015, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[78]  R. Benecke,et al.  Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus , 2015, Epilepsy & Behavior.

[79]  T. Tomson,et al.  Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII) , 2015, Epilepsy Research.

[80]  V. Kitchigina,et al.  Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs , 2015, Epilepsy Research.

[81]  T. Loddenkemper,et al.  Therapeutic choices in convulsive status epilepticus , 2015, Expert opinion on pharmacotherapy.

[82]  F. Zeiler.  Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus , 2015, Critical care research and practice.

[83]  W. Löscher,et al.  Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models. , 2015, European journal of pharmacology.

[84]  Chasity M. Shelton,et al.  Enteral topiramate in a pediatric patient with refractory status epilepticus: a case report and review of the literature. , 2014, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[85]  M. Rogawski,et al.  Pediatric super‐refractory status epilepticus treated with allopregnanolone , 2014, Annals of neurology.

[86]  M. Bialer,et al.  sec‐Butyl‐propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon‐induced status epilepticus in rats , 2014, Epilepsia.

[87]  D. Reddy.  Neurosteroids and their role in sex-specific epilepsies , 2014, Neurobiology of Disease.

[88]  I. Imran,et al.  Dynamics of hippocampal acetylcholine release during lithium‐pilocarpine‐induced status epilepticus in rats , 2014, Journal of neurochemistry.

[89]  F. Dudek,et al.  Valnoctamide enhances phasic inhibition: A potential target mechanism for the treatment of benzodiazepine‐refractory status epilepticus , 2014, Epilepsia.

[90]  R. Benecke,et al.  Possible effect of perampanel on focal status epilepticus after generalized tonic–clonic status epilepticus , 2014, Acta Neurologica Belgica.

[91]  Katsutoshi Ido,et al.  Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model , 2014, Pharmacology research & perspectives.

[92]  Anna Tarocco,et al.  Use of ketamine in a newborn with refractory status epilepticus: a case report. , 2014, Pediatric Neurology.

[93]  Quan Li,et al.  Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials , 2014, Journal of Anesthesia.

[94]  F. Jensen,et al.  Subunit composition of glutamate and gamma-aminobutyric acid receptors in status epilepticus , 2014, Epilepsy Research.

[95]  F. Zeiler,et al.  NMDA Antagonists for Refractory Seizures , 2014, Neurocritical Care.

[96]  B. Wlodarczyk,et al.  Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS‐active derivative of valproic acid with low teratogenic potential , 2014, Epilepsia.

[97]  D. Goldstein,et al.  Gaps and opportunities in refractory status epilepticus research in children: A multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG) , 2013, Seizure.

[98]  Patricia Dugan,et al.  Ketamine Continuous Infusion for Refractory Status Epilepticus in a Patient With Anticonvulsant Hypersensitivity Syndrome , 2013, The Annals of pharmacotherapy.

[99]  A. Cole,et al.  SGE‐102: A novel therapy for refractory status epilepticus , 2013, Epilepsia.

[100]  D. Reddy,et al.  Experimental Models of Status Epilepticus and Neuronal Injury for Evaluation of Therapeutic Interventions , 2013, International journal of molecular sciences.

[101]  M. Rogawski,et al.  Neuroactive steroids for the treatment of status epilepticus , 2013, Epilepsia.

[102]  M. Bialer,et al.  Valnoctamide and sec‐butyl‐propylacetamide (SPD) for acute seizures and status epilepticus , 2013, Epilepsia.

[103]  J. Szaflarski,et al.  Intravenous ketamine for the treatment of refractory status epilepticus: A retrospective multicenter study , 2013, Epilepsia.

[104]  D. Reddy.  Role of hormones and neurosteroids in epileptogenesis , 2013, Front. Cell. Neurosci..

[105]  K. Kelly,et al.  Ketamine use in the treatment of refractory status epilepticus , 2013, Epilepsy Research.

[106]  M. Falip,et al.  Causes of CNS Inflammation and Potential Targets for Anticonvulsants , 2013, CNS Drugs.

[107]  R. Dingledine,et al.  The role of inflammation in epileptogenesis , 2013, Neuropharmacology.

[108]  G. Testylier,et al.  Treatment of Status Epilepticus with Ketamine, Are we There yet? , 2013, CNS neuroscience & therapeutics.

[109]  D. Naylor,et al.  Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus , 2013, Neurobiology of Disease.

[110]  A. Kaufmann,et al.  Ketamine for Medically Refractory Status Epilepticus After Elective Aneurysm Clipping , 2013, Neurocritical Care.

[111]  S. Panchal,et al.  Reversal of experimentally induced seizure activity in mice by glibenclamide , 2013, Annals of Neurosciences.

[112]  S. Marsch,et al.  Topiramate as an Adjunctive Treatment in Patients with Refractory Status Epilepticus , 2012, CNS Drugs.

[113]  L. Mirabile,et al.  Efficacy and safety of ketamine in refractory status epilepticus in children , 2012, Neurology.

[114]  Paul M. Vespa,et al.  Guidelines for the Evaluation and Management of Status Epilepticus , 2012, Neurocritical Care.

[115]  D. Henshall,et al.  Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[116]  Annapurna Poduri,et al.  Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia , 2012, Annals of neurology.

[117]  K. Wilcox,et al.  A new derivative of valproic acid amide possesses a broad‐spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage , 2012, Epilepsia.

[118]  D. Naylor,et al.  Rational polytherapy in the treatment of acute seizures and status epilepticus , 2011, Epilepsia.

[119]  Simon Shorvon,et al.  The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. , 2011, Brain : a journal of neurology.

[120]  Andrea O Rossetti,et al.  Management of refractory status epilepticus in adults: still more questions than answers , 2011, The Lancet Neurology.

[121]  H. Goodkin,et al.  Treatment of Pediatric Status Epilepticus , 2011, Current treatment options in neurology.

[122]  A. Aertsen,et al.  Positive shifts of the GABAA receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus , 2011, Epilepsia.

[123]  A. Rossetti,et al.  Oral pregabalin as an add‐on treatment for status epilepticus , 2010, Epilepsia.

[124]  A. McGonigal,et al.  Generalized convulsive status epilepticus management in adults: A cohort study with evaluation of professional practice , 2010, Epilepsia.

[125]  D. Naylor.  Glutamate and GABA in the balance: Convergent pathways sustain seizures during status epilepticus , 2010, Epilepsia.

[126]  L. Velíšek,et al.  Females, their estrogens, and seizures , 2010, Epilepsia.

[127]  C. Hsieh,et al.  Terminating prolonged refractory status epilepticus using ketamine. , 2010, Clinical neuropharmacology.

[128]  S. Krishnamurthy,et al.  Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[129]  M. Wainwright,et al.  Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways , 2010, Brain Research.

[130]  G. Logroscino,et al.  Refractory status epilepticus: A prospective observational study , 2010, Epilepsia.

[131]  Chun-Yao Lee,et al.  Levetiracetam inhibits glutamate transmission through presynaptic P/Q‐type calcium channels on the granule cells of the dentate gyrus , 2009, British journal of pharmacology.

[132]  D. Naylor,et al.  Molecular basis of self‐sustaining seizures and pharmacoresistance during status epilepticus: The receptor trafficking hypothesis revisited , 2009, Epilepsia.

[133]  M. Shapira,et al.  Transcriptome Profiling Reveals TGF-β Signaling Involvement in Epileptogenesis , 2009, The Journal of Neuroscience.

[134]  F. Jensen,et al.  Epileptogenesis in the immature brain: emerging mechanisms , 2009, Nature Reviews Neurology.

[135]  P. Patsalos,et al.  Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam , 2009, Epilepsia.

[136]  E. Cavalheiro,et al.  Estrogen effects on pilocarpine-induced temporal lobe epilepsy in rats. , 2009, Maturitas.

[137]  H. Prüss,et al.  Ketamine successfully terminates malignant status epilepticus , 2008, Epilepsy Research.

[138]  C. Wasterlain,et al.  Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs , 2008, Epilepsia.

[139]  W. Löscher,et al.  Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus , 2008, Epilepsy Research.

[140]  F. Jensen,et al.  Early Alterations of AMPA Receptors Mediate Synaptic Potentiation Induced by Neonatal Seizures , 2008, The Journal of Neuroscience.

[141]  F. Jensen,et al.  Cell‐specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers , 2008, Annals of neurology.

[142]  J. Kapur,et al.  A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation , 2008, Epilepsia.

[143]  Faye S. Silverstein,et al.  Neonatal seizures , 2007, Annals of neurology.

[144]  M. Ciotti,et al.  Modulation of AMPA Receptors in Cultured Cortical Neurons Induced by the Antiepileptic Drug Levetiracetam , 2007, Epilepsia.

[145]  S. Sombati,et al.  Endocannabinoids block status epilepticus in cultured hippocampal neurons. , 2007, European journal of pharmacology.

[146]  E. Aronica,et al.  Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. , 2007, Brain : a journal of neurology.

[147]  W. Burnham,et al.  The anticonvulsant effects of allopregnanolone against amygdala-kindled seizures in female rats , 2007, Neuroscience Letters.

[148]  S. Sombati,et al.  Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy , 2007, Neuroscience Letters.

[149]  John W. Swann,et al.  Recurrent Seizures and the Molecular Maturation of Hippocampal and Neocortical Glutamatergic Synapses , 2006, Developmental Neuroscience.

[150]  L. Tassi,et al.  NMDA Receptor Composition Differs Among Anatomically Diverse Malformations of Cortical Development , 2006, Journal of neuropathology and experimental neurology.

[151]  F. Jensen,et al.  NKCC1 transporter facilitates seizures in the developing brain , 2005, Nature Medicine.

[152]  A. Auvinen,et al.  Treatment delay and the risk of prolonged status epilepticus , 2005, Neurology.

[153]  D. Naylor,et al.  Trafficking of GABAA Receptors, Loss of Inhibition, and a Mechanism for Pharmacoresistance in Status Epilepticus , 2005, The Journal of Neuroscience.

[154]  F. Dorandeu,et al.  Efficacy of the ketamine–atropine combination in the delayed treatment of soman-induced status epilepticus , 2005, Brain Research.

[155]  H. Goodkin,et al.  Status Epilepticus Increases the Intracellular Accumulation of GABAA Receptors , 2005, The Journal of Neuroscience.

[156]  C. Wasterlain,et al.  Anticonvulsant effects of levetiracetam and levetiracetam–diazepam combinations in experimental status epilepticus , 2004, Epilepsy Research.

[157]  B. Martin,et al.  The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[158]  G. Holmes,et al.  Diazepam Terminates Brief but Not Prolonged Seizures in Young, Naïve Rats , 2003, Epilepsia.

[159]  Jiankun Cui,et al.  Temporal and regional expression of NMDA receptor subunit NR3A in the mammalian brain , 2002, The Journal of comparative neurology.

[160]  Stephen Maren,et al.  Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus , 2002, Epilepsy Research.

[161]  Alberto Bacci,et al.  A Developmental Switch of AMPA Receptor Subunits in Neocortical Pyramidal Neurons , 2002, The Journal of Neuroscience.

[162]  F. Jensen,et al.  Maturational Aspects of Epilepsy Mechanisms and Consequences for the Immature Brain , 2001, Epilepsia.

[163]  P. Crino,et al.  Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia , 2001, Neurology.

[164]  C. Frye,et al.  Anti-seizure effects of progesterone and 3α,5α-THP in kainic acid and perforant pathway models of epilepsy , 2000, Psychoneuroendocrinology.

[165]  C. Wasterlain,et al.  N-methyl-d-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat , 1999, Neuroscience Letters.

[166]  R. Sheth,et al.  Refractory status epilepticus , 1998, Neurology.

[167]  D. Coulter,et al.  Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy , 1998, Nature Medicine.

[168]  B. Uthman,et al.  A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. , 1998, The New England journal of medicine.

[169]  R. Sankar,et al.  Self-sustaining status epilepticus after brief electrical stimulation of the perforant path , 1998, Brain Research.

[170]  M. Leśkiewicz,et al.  Effects of neurosteroids on kainate-induced seizures, neurotoxicity and lethality in mice. , 1997, Polish journal of pharmacology.

[171]  M. Rogawski,et al.  Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice , 1996, Neuropharmacology.

[172]  J. Kapur,et al.  Experimental status epilepticus alters γ‐aminobutyric acid type A receptor function in CA1 pyramidal neurons , 1995, Annals of neurology.

[173]  C. Frye.  The neurosteroid 3α,5α-THP has antiseizure and possible neuroprotective effects in an animal model of epilepsy , 1995, Brain Research.

[174]  D. Ferriero,et al.  Effect of prehospital treatment on the outcome of status epilepticus in children. , 1995, Pediatric neurology.

[175]  A. Brooks-Kayal,et al.  Developmental changes in human γ‐aminobutyric acida receptor subunit composition , 1993, Annals of neurology.

[176]  W. Hauser,et al.  Incidence of Epilepsy and Unprovoked Seizures in Rochester, Minnesota: 1935–1984 , 1993, Epilepsia.

[177]  B. Sakmann,et al.  Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit , 1992, Neuron.

[178]  Orrin Devinsky,et al.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. , 2017, The New England journal of medicine.

[179]  M. Doyle-Waters,et al.  The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review. , 2015, Annals of emergency medicine.

[180]  B. Krauss,et al.  Ketamine and intracranial pressure: no contraindication except hydrocephalus. , 2015, Annals of emergency medicine.

[181]  A. Asadi-Pooya,et al.  Treatment of refractory generalized convulsive status epilepticus with enteral topiramate in resource limited settings , 2015, Seizure.

[182]  Doodipala Samba Reddy,et al.  Neurosteroids: endogenous role in the human brain and therapeutic potentials. , 2010, Progress in brain research.

[183]  C. Frye.  Chapter 3 Hormonal Influences on Seizures , 2008 .

[184]  Norman Delanty,et al.  Chapter 2 Epidemiology and Classification of Epilepsy , 2008 .

[185]  P. Mcnaughton,et al.  Glial cell responses to lipids bound to albumin in serum and plasma. , 2001, Progress in brain research.

[186]  Treiman Dm,et al.  Rational polytherapy in the treatment of status epilepticus. , 1996 .

[187]  D. Treiman,et al.  Rational polytherapy in the treatment of status epilepticus. , 1996, Epilepsy research. Supplement.